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ABSTRACT 
Purpose: To explore the effect of NFB activation in macrophages on osteoclastogenesis of 
bone marrow cells for potential application as a new type of therapy for preventing bone loss.  
Methods: Primary cultured macrophages and bone marrow cells were prepared from mice.  As 
macrophage-targeted carriers, Mannosylated cationic liposomes (Man-liposomes) were prepared 
and were allowed to form complexes with NFB decoy (a double-stranded oligonucleotide).  
Cellular uptake, inhibition of NFB activation, and cytokine production were evaluated using 
macrophages.  Osteoclastogenesis was investigated using bone marrow cells, which were 
cultured in the conditioned medium prepared from macrophages with or without Man-
liposome/NFB decoy complexes treatment.   
Results: Cellular accumulation of NFB decoy was enhanced by Man-liposome.  NFB 
activation in macrophages and TNF- production were suppressed in macrophages by Man-
liposome/NFB decoy complexes but not by the naked NFB decoy, Gal-liposome/NFB decoy 
complexes, or Man-liposome/random decoy complexes.  Osteoclastogenesis of bone marrow 
cells was induced in the conditioned medium prepared from activated macrophages but not by 
activated macrophages treated with Man-liposome/NFB decoy complexes.  
Conclusion: Osteoclastogenesis induced by activated macrophages could be suppressed by the 
treatment macrophages with Man-liposome/NFB decoy complexes.  Macrophage-targeted 
delivery of NFB decoys using Man-liposomes may be promising in its use for the remediation 
of bone loss. 
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INTRODUCTION 
A large proportion of the world’s population has rheumatoid arthritis (RA), which is a 
systemic autoimmune disease characterized by chronic inflammation of the synovium that 
spreads to the cartilage and bone, leading to bone destruction (1).  Moreover, bone destruction is 
a severe problem in osteoporosis and periodontitis (2).  In RA, there is a marked increase in the 
production of the proinflammatory cytokines tumor necrosis factor (TNF) and receptor activator 
NF-kappa B ligand (RANKL), which is members of the TNF family that are known to stimulate 
bone resorption by osteoclasts (3,4).  In RA, the synergistic relationship between TNF- and 
RANKL serves to enhance the osteoclastogenic properties of both proinflammatory cytokines 
(5,6).  TNF- functions in a manner similar to that of RANKL and not other osteoclast-
stimulating factors; and it directly promotes osteoclast differentiation via its Type 1 or 55 
receptors (7).  Furthermore, severe arthritis model mice which have similar patholocy to the 
human pathology could be established by overexpressing human TNF in mice (8).  Therefore, 
TNF- is likely to be one of the key cytokines in RA therapy.  In fact, anti-TNF- agents have 
significantly improved the symptoms and disabilities of patients with RA (9).  However, some 
anti-TNF- drugs have been recently found to interfere with innate immune responses such as 
phagolysosome maturation and monocyte apoptosis (10); hence, new therapeutic agents are 
required.   
In macrophages, the production of TNF- is centrally regulated by the transcription 
factor nuclear factor kappa B (NFB) (11,12).  Because a magnified activation of NFB in 
macrophages occur at the site of inflammation, the act of suppressing NFB activation by NFB 
inhibitors has been demonstrated to be beneficial for use in inflammation therapy (13).  Being an 
inhibitor of NFB, the double-stranded oligonucleotide with the binding sequence to the 
transcription factor NFB, referred to as the NFB decoy, is an attractive drug candidate because 
the NFB decoy suppresses excess NFB activation in a sequence-dependent manner (14).  
Therefore, NFB decoy is expected to hardly affect innate immune response, and consequently 
to work with a small number of unexpected side effects.  However, the use of NFB decoy in 
vivo is limited due to its low cellular permeability, which is caused by large amount of anionic 
charge on the molecule (15,16).  Therefore, it is necessary to develop suitable carriers for 
delivering NFB decoy to the target cells.   
To date, several delivery carriers for NFB decoy have been developed; they include 
hemagglutinating virus of Japan-envelope liposomes (HVJ liposomes) (17), cationic liposomes 
(18,19), PLGA microspheres (20), folate liposome (21), and dendritic poly(l-lysine)(22).  As far 
as the macrophage-selective targeting is concerned, we developed the mannosylated cationic 
liposomes (Man-liposomes) for use in plasmid DNA delivery (23) because mannose receptors 
are found in high numbers on macrophages.  More recently, we have demonstrated that 
intravenously injected Man-liposomes/NFB decoy complexes were efficiently taken up by 
Kupffer cells, liver macrophages, and liver endothelial cells via mannose receptors and 
functioned to suppress lipopolysaccharide(LPS)-induced cytokine production by macrophages in 
a liver failure model (24).  In RA, macrophages in the articular cavity release cytokines, which 
promote severe inflammation and osteoclastogenesis.  Therefore, targeted delivery of NFB 
decoys by Man-liposomes would be a promising approach for treating RA.  However, the 
mechanism of bone loss in RA is extremely complicated because various types of cells 
participate in evoking the bone loss in more closed space than systemic space.  Currently, there is 
little information regarding the relationship between proinflammatory cytokine production from 
NFB-activated macrophages and osteoclastogenesis of precursor cells.  In oder to develop new 
therapy for RA by targeted delivery of NFB decoy using Man-liposomes, it is nesessary to 
investigate that osteoclastgenesis could be suppressed by the inhibition of cytokines production 
from macrophage in vitro because its contribution would be clearly evaluated in the simple 
system.  
In this study, we prepared primary cultured macrophages isolated from mice and 
confirmed their time-course expression levels of mannose receptors.  We then investigated the 
cellular uptake characteristics and inhibitory effects of Man-liposomes/NFB decoy complexes 
on TNF- production and NFB activation.  Finally, we evaluated osteoclastogenesis of 
precursor cells, bone marrow cells prepared from mice, by analyzing secretions from 
macrophages treated with Man-liposome/NFB decoy complexes.   
MATERIALS AND METHODS 
 
Materials  
Oligonucleotides (diester type) (NFB decoy: 5′ -AGTTGAGGGGACTTTCCCAGGC-3′
/5 ′ -GCCT CCCAAAGTCCCCTCAACT-3 ′ ; random decoy: 5 ′ -
TTGCCGTACCTGACTTAGC C-3 ′ /5 ′ -GGCT AAGTCAGGTACGGCAA-3 ′ ) and 
rhodamine labeled oligonucleotides (diseter type) were purchased from Hokkaido System 
Science Co., Ltd. (Hokkaido, Japan). Oligonucleotide (thioate type) were kindly provided by 
Anges MG Inc. (Osaka, Japan).  N-(4-aminoethyl) carbamic acid tert-butyl ester was obtained 
from Tokyo Kasei Kogyo Co. Ltd. (Tokyo, Japan).  Dioleoylphosphatidylethanolamine (DOPE) 
was obtained from Avanti Polar Lipids Inc. (Alabaster, AL, USA).  Cholesteryl chloroformate 
was purchased from Sigma Chemicals Pvt. Ltd. (St Louis, MO, USA).  
 
Synthesis of Man-C4-Chol  
Man-C4-Chol was synthesized as previously reported (23).  Briefly, cholesteryl chloroformate 
and N-(4-aminobutyl)carbamic acid tert-butyl ester were allowed to react in chloroform for 24 h 
at 4°C.  A solution of trifluoroacetic acid and chloroform was added dropwise and the mixture 
was stirred for 2 h at 4°C.  The solvent was then evaporated in order to obtain the N-(4-
aminobutyl)-(cholesten-5-yloxyl)formamide, which was then combined with 2-imino-2-
methoxyethyl-1-thiomannoside for 24 h at room temperature.  After evaporation, the resulting 
precipitate was suspended in water, dialyzed against distilled water for 48 h, and finally 
lyophilized.  Gal-C4-Chol was synthesized by the same protocol with Man-C4-Chol after 
preparation of 2-imino-2-methoxyethyl-1-thiogalactoside.   
 Preparation of Man-liposomes and Man-liposomes/NFB decoy complexes 
Man-C4-Chol was mixed with DOPE in chloroform at the molar ratio of 3:2.  The mixture was 
then dried, vacuum desiccated, and the precipitate resuspended in sterile 5% dextrose.  After 
hydration for 30 min at room temperature, the suspension was sonicated for 10 min in a bath 
sonicator and for 3 min with a tip sonicator in order to form Man-C4-Chol/DOPE liposomes 
(Man-liposomes).  The Man-liposome/NFB decoy complexes were prepared by using the 
method previously described (24).  Equal volumes of NFB decoy and stock Man-liposome 
solution was diluted by the addition of 5% dextrose at room temperature.  Then, the NFB decoy 
solution was rapidly added to the liposome solution.  This mixture was agitated by pumping it up 
and down twice in the pipette tip.  Finally, the mixture was left at room temperature for 30 min.  
NFB decoy or random was complexed with Man- or Gal-liposomes at a charge ratio of 2.3 : 1.0 
(+:-) following previous reports (19,24), because complexes with liposomes containig DOPE  
were stable at this mixing ratio in vivo (25).  Particle sizes and zeta potentials of Man-liposomes 
and Man-liposome/NFB decoy complexes were determined using a Zetasizer Nano ZS 
instrument (Malvern Instruments, Ltd., UK). 
 
Preparation of primary cultured macrophages and bone marrow cells from mouse 
Five-week-old female ICR mice and 6-week-old female C57BL6/crSlc mice were obtained from 
Shizuoka Agricultural Cooperative Association for Laboratory Animals (Shizuoka, Japan).  All 
animal experiments were carried out in accordance with the Principles of Laboratory Animal 
Care as adopted and promulgated by the US National Institute of Health and the Guidelines for 
Animal Experiments of Kyoto University.  Elicited peritoneal macrophages were prepared by 
using the method previously described (26). Briefly, cells were harvested from ICR mice or 
C57BL6/crSlc mice 4 days after intraperitoneal injection of 1 ml 2.9% thioglycolate medium 
(Nissui Pharmaceutical, Tokyo, Japan).  The washed cells were suspended in RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS) (Flow Laboratories, Irvine, UK), 
penicillin G (100 U/ml), and streptomycin (100 g/ml) and the medium was then plated either on 
6- or 24-well plates (Falcon, Becton Dickinson, Lincoln Park, NJ, USA) at a density of 1 × 106 
cells/cm2.  After incubation for 2 h at 37°C in an atmosphere of 5% CO2 and 95% air, non-
adherent cells were washed off.  The remaining cells were cultured for 24, 48, 72, or 96 h.  
Mouse bone marrow cells were collected according to the procedure described by Yagi K (27).  
In brief, bone marrow cells were isolated from mice by flushing the femurs with DMEM 
containing 10% FBS, 1000 U/ml penicillin G, 100 mg/l streptomycin, 100 g/l amphotericin B, 
and 100 g/l aprotinin using a 25-gauge needle.  Isolated cells were seeded onto 24-well dishes 
at a density of 1.5 × 106 cells/cm2 and cultured in DMEM at 37°C in a humidified atmosphere of 
5% CO2 and 95% air.   
 
Immunohistochemistry of mannose receptors on macrophages 
After the macrophages were washed twice with PBS, cells were fixed with 4% paraformaldehyde 
in PBS for 10 min.  Next, the cells were washed with 10 mM glycine in PBS in order to quench 
the aldehyde group, and then, they were incubated with 3% BSA in PBS for 30 min at room 
temperature to accomplish effective blocking.  After washing the cells with 10 mM glycine in 
PBS, the cells were incubated with 10 g/ml FITC labeled with anti-CD206 antibody 
(MCA2235FA) (AbD Serotec, Kidlington, UK) for 1 h at room temperature under shading.  The 
cells were washed with 0.1% BSA in PBS 3 times and then incubated with 10 g/ml DAPI 
(4′,6-diamidine-2′-phenylindoledihydrochloride) for 1 min in order to stain the nuclei.  After 
washing once with PBS, cover glasses were mounted on slide glasses with 50% glycerol-2.5% 
DABCO (1,4-diazabicyclo-[2,2,2]octane) (Sigma Chemical Co., Inc., St. Louis, MO, USA)- PBS.  
The samples were observed using fluorescent microscopy (Biozero, Keyence Corp., Osaka, 
Japan). 
 
Uptake of NFB decoy in macrophages  
In order to allow observation by microscopy, macrophages were cultured on cover glasses.  
Macrophages were treated with rhodamine-NFB decoy, Man-liposome/rhodamine-NFB decoy 
complexes, or Gal-liposome/NFB decoy complexes in OptiMEM® for 6 h before being 
challenged with 200 ng/ml LPS in OptiMEM® in 4 h at 37°C.  Then, the cells were washed with 
PBS and fixed with 4% paraformaldehyde in PBS for 10 min.  Cell nuclei were stained with 10 
g/ml DAPI for 1 min.  After washing once with PBS, cover glasses were mounted on slide 
glasses and observed by fluorescent microscopy (Biozero, Keyence Corp., Osaka, Japan).   
 
Measurement of cytokine and NFB 
For the measurement of cytokines and NFB, primary cultured macrophages were cultured with 
naked NFB decoy, Man-liposome/NFB decoy complexes, Gal-liposome/NFB decoy 
complexes, or Man-liposome/random decoy complexes with or without mannose in OptiMEM® 
for 6 h at 37°C.  Then, the cells were cultured in 0.2 g/ml LPS in OptiMEM® for 4 h at 37°C.  
When the effect of backbone of NFB decoy was investigated, NFB decoy and LPS were co-
cultured for indicated time.  After that, the supernatants were collected and used for the 
determination of TNF- using an ELISA kit (eBioscience, San Diego, CA, USA).  Nuclear 
extracts of macrophages were prepared using the Nuclear/Cytosol fractionation kit (Pierce, USA).  
The amounts of activated NFB in the nuclear extract of cells were measured using a 
Chemiluminescent electrophoretic mobility shift assay (EMSA) kit (Pierce Biotechnology, Inc., 
USA) according to the manufacturer's protocol.  The competition reaction was measured by 
using a 2000-fold molar excess of unlabeled NFB probe.  
 
Osteoclastogenesis assay 
After our macrophages were incubated with 0.2 g/ml LPS in OptiMEM® for 4 h, supernatant 
were mixed with DMEM at a volume ratio of 1:3 and then MCSF and RANKL were added to the 
medium at the final concentration of 10 ng/ml for each (called conditioned medium).  After 
replacing the medium, bone marrow cells were incubated in the conditioned medium for 72 h.  
The cells were washed and fixed with 10% formalin.  Finally, the cells were stained with tartrate-
resistant acid phosphatase (TRAP) and observed using a lightmicroscope (Biozero, Keyence 
Corp., Osaka, Japan). 
 
Statistical analysis  
Statistical comparisons were performed using a two-tail unpaired Student's t test for 2 groups.  A 
value of p < 0.05 was considered statistically significant.  For more than 3 groups, data were 
analyzed by ANOVA, and Bonferroni/Dunn procedure was used as a post hoc test.  
RESULTS AND DISCUSSION 
Particle size and zeta potential of Man-liposomes and their complexes with NFB 
decoy 
In our study, Man-liposomes were prepared using DOPE and Man-C4-Chol as carriers for 
NFB decoy due to the molecule’s ability to facilitate macrophage-targeted delivery.  Firstly, the 
cationic charge on Man-C4-Chol would facilitate binding with the negative charge present on the 
NFB decoy.  Secondly, mannose molecules conjugated with the liposomes allowed specific 
binding to mannose receptors, which are present in large numbers on the surface of the 
macrophage.  Finally, the helper lipid (DOPE) in Man-liposomes may accelerate the escape of 
NFB decoy from the endosomes into the cytoplasm, thus avoiding lysosomal degradation.  
Then, NFB decoy could be delivered to its active site in the cytosol and nuclei. 
At first, we measured the mean diameter and zeta potential of Man-liposomes and Man-
liposome/NFB decoy complexes.  The mean diameters of Man-liposome/NFB decoy 
complexes were slightly higher than that of Man-liposome but still less than 100 nm.  The Zeta 
potential of Man-liposomes/NFB decoy complexes was slightly smaller than that of Man-
liposomes (Table 1).  This result suggests that the cationic charge was remaining on Man-
liposome/NFB decoy complexes.  As a result, the cationic charge on the complexes could be 
used to aid in attachment to the surface of the cells.   
Inhibitory effect of Man-liposomes/NFB decoy complexes on TNF- production 
in macrophages 
The expression of mannose receptor on primary cultured macrophages isolated form mice 
was immunehistchemically stained.  Although the expression of mannose receptor was not 
observed on the next day after cells were harvested, the expression of mannose receptor was 
recovered on 3rd and 4th days (Fig. 1).  To evaluate the suitability of Man-liposome/NFB decoy 
complexes for use in the treatment of chronic inflammatory conditions, the decoy’s inhibitory 
effect on TNF- production was investigated in primary cultured macrophages.  LPS-induced 
TNF- production was significantly inhibited by Man-liposome/NFB decoy complexes but not 
by naked NFB decoy (Fig. 2A).  It was noted that the strength of the inhibition of TNF- 
production was directly proportional to the amount of NFB present in the complex with Man-
liposome (Fig. 2A).  In the presence of excessive amounts of mannose, the inhibitory effect on 
TNF- production by Man-liposome/NFB decoy complexes was not observable.  On the other 
hand, the inhibitory effect of Gal-liposome/ NFB decoy complexes was not affected by the 
presence of excessive amounts of mannose (Fig. 2B).  These results suggest that mannose 
receptors mediate the uptake of Man-liposome/NFB decoy complexes by macrophages.  Gal-
liposome/NFB decoy complexes also surpress TNF- production to some extent.  In orderto 
make complexes electrostatically with oligonucleotide, Man-C4-Chol and Gal-C4-Chol have 
positive charge on itself.  Therefore, the data of zeta potential demonstrated thta Man- or Gal-
liposome and its complexes with oligonucleotide have positive charge.  The inhibitory effect of 
Gal-liposome/NFB decoy complexes would be explained by the effect of the positive charge.  
However, in our previous reports, the effect of positive charge on the complexes is enough small 
for targeted delivery through the receptor mediated uptake in vivo (23, 24)  
In order to evaluate the effect of the sequence of decoy on TNF- production, random decoy, 
which did not include the NFB-binding sequence was transfected to macrophage by Man-
liposome.  While Man-liposome/NFB decoy complexes effectively suppressed LPS-induced 
TNF- production from macrophages, Man-liposome/random decoy complexes did not inhibit 
LPS-induced TNF- production from macrophages, suggesting that the strong inhibitory effect 
of Man-liposome/NFB decoy complexes was dependent on the sequence (Fig. 3A).   
An oligonucleotide with a “natural” phosphodiester backbone is rapidly degraded by 
nucleaseses (28).  In order to prevent degradation by nucleases, several types of chemically 
modified oligonucleotides were developed using phosphorothioate, methylphosphonate, and 
phosphoramidate (29,30).  Of these chemically modified oligonucleotides, phosphorothioate-
modified oligonucleotide advanced in clinical trials (30).  NFB decoy with phosphorothioate 
modification was also reported in vivo and in vitro (31).  However, previous reports 
demonstrated that unexpected immunostimulation was caused by phosphorothioate modification 
in cultured murine splenic lymphocytes (32) and in cultured human B cells (33).  In order to 
investigate the effect of phosphorothioate modification, we compared the inhibitory effect of 
NFB decoy on TNF- production with a NFB decoy that had been modified with 
phosphorothioate.  Both naked NFB decoy with the natural phosphodiester backbone and that 
with phosphorothioate modification did not inhibit LPS-induced TNF- production from 
macrophages (Fig. 3B).  Man-liposome complexed with NFB decoy having a phosphodiester 
backbone or thioate bond showed the same extent of inhibition on LPS-induced TNF- 
production from macrophages (Fig. 3B).  This result indicated that phosphorothioate 
modification does not influence the inhibitory effect of NFB decoy in cultured macrophages in 
this extent of decoy’s concentration.     
Intracellular accumulation of Man-liposomes/NFB decoy complexes in 
macrophages 
In order to evaluate mannose receptor mediated uptake of Man-liposome/NFB decoy 
complexes, intracellular accumulation of a rhodamine-NFB decoy transfected by Man-liposome 
or Gal-liposome were observed by using fluorescent microscopy.  Intracellular accumulation of 
rhodamine-NFB decoy was more enhanced by Man-liposome than by Gal-liposome (Fig. 4).  
Moreover, excessive amounts of mannose strongly inhibited the uptake of Man-
liposome/rhodamine-NFB decoy complexes but not Gal-liposome/rhodamine-NFB decoy 
complexes (Fig. 4).  These results correlated well with the result that the inhibitory effect of 
Man-liposome/NFB decoy complexes on TNF- production was suppressed by excessive 
amounts of mannose (Fig. 2A).  These results support the hypothesis that mannose receptor 
mediates the uptake of Man-liposome/NFB decoy complexes.   
Previously, we have demonstrated that intravenously injected Man-liposome/NFB decoy 
complexes accumulated in liver nonparenchymal cells consisting of Kupffer cells and endothelial 
cells, both of which express mannose receptors (24).  Moreover, intratracheally injected Man-
liposome/NFB decoy complexes accumulated in macrophages isolated from lung tissue (34).  
In this study, mannose receptor-mediated uptake of Man-liposome/NFB decoy complexes was 
directly demonstrated using primary cultured macrophages, for the first time, by the observed 
inhibitory effect of mannose.  These data support the existence of a relationship between the 
recognition of mannose receptors and macrophage-targeted delivery of NFB decoy by Man-
liposome in mice.      
Inhibitory effect of Man-liposomes/NFB decoy complexes on NFB activation in 
macrophages 
NFB is a transcription factor that regulates the expression of various cytokines in 
macrophages.  In response to stimuli, IB protein degraded and allowed NFB to translocate into 
the nuclei.  Activated NFB was captured by the transfected NFB decoy and as a result, the 
transcription of NFB could be suppressed (13).  To investigate NFB activity, the amount of 
NFB in the nuclei was measured using EMSA.  The amount of activated NFB dramatically 
increased when macrophages were cultured with LPS (Fig. 5).  When an excessive amount of 
non-labeled anti NFB probe was applied to the nuclear extract of LPS-treated macrophages, the 
signal band became pale.  This suggests that the signal band is actually the band of NFB.  This 
LPS-induced activation of NFB could be effectively suppressed by Man-liposome/NFB decoy 
complexes but not by naked NFB decoy or Man-liposome/random decoy complexes (Fig. 5).  
This result scorrelated well with the inhibitory effect on TNF- production (Fig. 2B, 3A).   
Inhibitory effect of Man-liposomes/NFB decoy complexes on osteoclastgenesis 
In order to investigate whether the suppression of cytokine production in macrophages could 
prevent osteoclastogenesis, marrow cells were cultured in conditioned media in the presence of 
RANKL and M-CSF.  The conditioned media was collected from LPS-treated macrophages and 
contained several cytokines such as TNF-.  The number of TRAP-positive cells was 
significantly larger than the bone marrow cells treated with RANKL and M-CSF, but not the 
cells cultured in media collected from LPS-treated macrophages.  This suggests that secretions 
from macrophages could enhance osteoclastogenesis (Fig. 6).  This increase in the number of 
TRAP-positive cells was not observed when bone marrow cells were cultured in the media that 
was collected from LPS-treated macrophages cultured with Man-liposome/NFB decoy 
complexes (Fig. 6).  On the other hand, the number of TRAP-positive cells, which were cultured 
in the media obtained from LPS-treated macrophages that had been cultured with naked NFB 
decoy or Man-liposome/random decoy complexes, was smaller when compared with those 
cultured in conditioned media from LPS-treated macrophages that had been exposed to Man-
liposome/NFB decoy complexes.  These results suggest that secretion under the regulatory 
control of NFB in macrophages may promote osteoclastogenesis in bone marrow cells.  
Therefore, inhibition of NFB activation in macrophage might be sufficient to suppress 
osteoclastogenesis.   
RANKL and TNF- activate p50/RelA dimers in the canonical NFB pathways in osteoclast 
precursors, which then promote osteoclast differentiation (13).  Thus, NFB in osteoclast 
precursors is believed to play a pivotal role in osteoclastogenesis.  Shimizu et al. demonstrated 
that the transfection of naked NFB into osteoclast precursor cells prevents osteoclastogenesis 
induced by 1,25-dihydroxyvitamin D3 or combinational stimulation of RANKL and M-CSF in 
culture cells.  Moreover, when naked NFB decoy is transfected in an ovariectomy rat model via 
the implantation of osmotic minipumps containing NFB decoy, the increase in the number of 
TRAP-positive cells and the decrease of Ca in the bone was inhibited (35)  Thus, transfection of 
NFB decoy is likely to be an effective therapy for bone loss.  However, the uptake of naked 
oligonucleotides is extremely low due to its negative charge.  Moreover, the possible dose of 
NFB decoy for intraarticular injection was limited by the narrow space of the articular cavity.  
Furthermore, although targeted delivery of NFB decoy to osteoclast precursor cells is important, 
the multiplicities in the expression of cell surface protein on precursor cells serves as an obstacle 
in the development of a delivery system for osteoclast precursor cells.  After having taken all of 
these factors into consideration, it is apparent that the inhibition of cytokine production from 
macrophages by Man-liposome/NFB decoy complexes is a potential approach for preventing 
bone loss.   
  
CONCLUSIONS 
We demonstrated, for the first time, the enhanced uptake of NFB decoy complexes and the 
inhibitory effect on NFB activation and TNF- production in LPS-treated macrophages by 
Man-liposomes/NFB decoy complexes in primary cultured macrophages.  Moreover, 
osteoclastogenesis was effectively induced by the conditioned medium prepared by using 
activated macrophages, but it was induced to a lesser extent by the conditioned medium prepared 
by activated macrophages treated with Man-liposomes/NFB decoy complexes.  Although 
further studies using bone loss model mouse are required, these results suggest that Man-
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RA rheumatoid artitis 






Fig. 1 Immunohistochemical staining of mannose receptors on primary cultured macrophages.  
Macrophages isolated from ICR mice were plated for 1, 2, 3, and 4 days, and labeled with anti 
CD206 antibody (green) and DAPI (blue).  
 
Fig. 2 Inhibitory effect on TNF- production.  (A) Effect of NFB decoy dose.  Primary 
cultured macrophages were cultured with naked NFB decoy (open circle) or Man-
liposome/NFB decoy complexes (closed circle) for 6 h at concentrations of 0, 0.5, 1, and 2 M.  
After the cells were washed with PBS, cells were cultured in OptiMEM containing LPS (200 
ng/ml) for 4 h.  Significant difference *** P < 0.001, v.s. (naked NFB decoy).  (B) Effect of 
excessive amounts of mannose.  Primary cultured macrophages were cultured with Man-
liposome/NFB decoy complexes, or Gal-liposome/NFB decoy complexes for 6 h at 
concentrations of 2 M with (white) or without (black) 20 mM mannose.  After cells were 
washed with PBS, cells were cultured in OptiMEM containing LPS (200 ng/ml) for 4 h.  
 
Fig. 3 Inhibitory effect on TNF- production.  (A) Effect of sequence of NFB decoy.  Primary 
cultured macrophages were cultured with naked NFB decoy, Man-liposome/NFB decoy 
complexes, or Man-liposome/random decoy complexes for 6 h at a concentration of 2 M.  After 
the cells were washed with PBS, cells were cultured in OptiMEM containing LPS (200 ng/ml) 
for 4 h.  Significant difference ### P < 0.001, v.s. (LPS), *** P < 0.001, v.s. (naked NFB 
decoy),  P < 0.001 v.s. (Man-liposome/random decoy).   (B) Effect of backbone in NFB 
decoy.  Primary cultured macrophages were cultured with naked NFB decoy with a 
phosphodiester backbone (open triangle) or phosphorothioate modification (closed triangle), or 
NFB decoy with a phosphodiester backbone (open circle) or phosphorothioate modification 
(closed circle) complexed with Man-liposome for 1, 3, 6 and 12 h at a concentration of 2 M 
under existence of LPS (200 ng/ml).  As a control, cells (without NFB decoy) were cultured 
with (closed square) or without (cross) LPS (200 ng/ml).  Significant difference *** P < 0.001, 
v.s. (naked NFB decoy with a phosphorothioate backbone),  P < 0.001  v.s. (naked NFB 
decoy with a phosphodiester backbone).       
 
Fig. 4 Intracellular accumulation of rhodamine-NFB decoy, Man-liposome/rhodamine-NFB 
decoy or Gal-liposome/rhodamine-NFB decoy with or without excessive amounts of mannose.  
Primary cultured macrophages were cultured with (A) rhodamine-NFB decoy (red), (B) Man-
liposome/rhodamine-NFB decoy (red), or (C) Gal-liposome/rhodamine-NFB decoy (red) for 6 
h at 2 M with or without 20 mM mannose.  After the cells were washed with PBS, they were 
cultured in OptiMEM containing LPS (200 ng/ml) for 4 h.  Then, the nuclei were stained with 
DAPI (blue) after fixing with paraformaldehyde. 
 
Fig. 5 Inhibitory effect on NFB activation.  Primary cultured macrophages were cultured with 
naked NFB decoy, Man-liposome/NFB decoy complexes, or Man-liposome/random decoy 
complexes for 6 h at 2 M.  After the cells were washed with PBS, they were cultured in 
OptiMEM containing LPS (200 ng/ml) for 4 h.  Then, nuclear protein was extracted and 
evaluated using EMSA.   
 
Fig. 6 Inhibitory effect of osteoclastogenesis.  Primary cultured macrophages were cultured with 
naked NFB decoy, Man-liposome/NFB decoy complexes, or Man-liposome/random decoy 
complexes for 6 h at 2 M.  After the cells were washed with PBS, they were cultured in 
OptiMEM containing LPS (200 ng/ml) for 4 h.  Then, conditioned media was prepared with 
collected conditioned medium and DMEM.  Bone marrow cells were cultured in the conditioned 
medium for 72 h.  After fixing with 10% formalin, the cells were stained with TRAP. 
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Table 1  Mean particle sizes and zeta potential of liposomes and 





Man-liposomes 63.8 ± 0.6 42.9 ± 0.7
Man-liposome/
NFB decoy complexes 87.5 ± 5.0 36.1 ± 0.3
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(C) Gal-liposome/Rhodamine-NFB decoy
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(C) Naked NFB decoy
(D) Man-liposome/NFB decoy
(E) Man-liposome/random decoy 
